If you are looking at AMAG, look at RMTI too. Like AMAG, they have a new iron therapy drug to treat anemia. Initially targeting end-stage renal disease w/ addressable market of 2M patients by 2010. They are doing another Phase II & if successful should start III in 2009. Only pure play iron play left that still cheap. Reply
loading ...
Editors
General Discussion on ALTU
Is this a buy or a sell? Reply2007 Biotech Performance Review [view article]
If you are looking at AMAG, look at RMTI too. Like AMAG, they have a new iron therapy drug to treat anemia. Initially targeting end-stage renal disease w/ addressable market of 2M patients by 2010. They are doing another Phase II & if successful should start III in 2009. Only pure play iron play left that still cheap. Reply2007 Biotech Performance Review [view article]
looks great Reply